05:33 AM EDT, 04/02/2026 (MT Newswires) -- Roivant Sciences ( ROIV ) unit Priovant Therapeutics said Thursday it launched a new phase 2b/3 clinical program for brepocitinib in lichen planopilaris, an inflammatory scalp disorder, with the first subjects enrolled in March.

The US Food and Drug Administration recently granted priority review to brepocitinib's new drug application for dermatomyositis, with a target action date in Q3, according to the company.